OXT THerapeutics is a biotech firm organized around treating diseases where pathologic defects in oxytocin signaling are involved - e.g. obesity. Working on novel activators of the oxytocin receptor networks to treat metabolic disorders, OXT Therapeutics (OXTT) is developing potent, safe, longitudinally active, selective, metabolically stable and non-CNS permeable agents that modulate Oxytocin (OXT)/Oxytocin Receptor (OXTR) signaling network. A primary focus is on first-in-class agents that treat obesity, bone and skeletal muscle diseases. Principals of the firm have identified multiple proprietary and diverse low pM agonists of OXTR with > 1,000+ selectivity over vasopressin receptors, dramatically enhanced metabolic stability vs parent OXT and efficacy in rat models of obesity
